26DT052; Scaling Busulfan Dose to Body Surface Area in Children
25. august 2026 opdateret af: Children's Hospital of Philadelphia
Pilot Study of Scaling Busulfan Dose to Body Surface Area in Children Undergoing Hematopoietic Stem Cell Transplantation
The goal of this pilot study is to determine if scaling the first busulfan dose to Body Surface Area (BSA) in children with a BSA ≥0.5 m2 and using a BSA-banded dosing table for infants (BSA <0.5 m2) increases the fraction of patients achieving a therapeutic drug exposure after the first dose.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Busulfan is a drug used in conditioning regimens for bone marrow transplantation.
Busulfan levels outside the desired range can cause excessive side effects or failure of bone marrow engraftment.
The initial dose of busulfan is currently scaled to body weight; on subsequent days the dose may be adjusted to achieve busulfan levels in a therapeutic range.
However, only half of children receiving a busulfan dose scaled to body weight achieve therapeutic blood levels after the first dose.
We performed computer simulations of alternative dosing methods for infants and children, and identified that dosing based on body surface area (BSA) could significantly increase the number of children achieving therapeutic blood levels after the first dose.
This study will test whether this new dosing method results in a higher percentage of patients achieving the desired busulfan blood levels after the first dose.
The study will enroll up to 38 children receiving high doses of busulfan as part of their standard conditioning regimen prior to bone marrow transplant.
We will use the busulfan blood levels that are routinely measured after the first dose to determine the effectiveness of our new dosing method.
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
38
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Meghan Donnelly, MPH
- Telefonnummer: 267-426-9343
- E-mail: donnellymt@chop.edu
Undersøgelse Kontakt Backup
- Navn: Ruchi Singh, PhD
- E-mail: singhr3@chop.edu
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19103
- Children's Hospital of Philadelphia
-
Ledende efterforsker:
- Frank Balis, MD
-
Kontakt:
- Meghan Donnelly, MPH
- Telefonnummer: 267-426-9343
- E-mail: donnellymt@chop.edu
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Subject age: ≤21 years
Body Surface Area (BSA):
- Group A: BSA ≥0.5 m2
- Group B: BSA <0.5 m2
- Planned for once-daily busulfan-containing conditioning regimen pre-bone marrow transplant
- Scheduled to have TDM after the first dose of busulfan
- Diagnosis: both benign and malignant conditions are eligible
Exclusion Criteria:
1. At the time of enrollment, patients may not receive medications that significantly alter busulfan clearance, as specified below.
a. If patients had received the drugs listed below prior to enrollment, the following washout periods, based on ≥ 6 times drug t½, are required.
Deferasirox: ≥7 days Metronidazole: ≥7 days Ketoconazole, voriconazole: ≥7 days Itraconazole, posaconazole: ≥14 days Phenytoin: ≥21 days
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Group A
Patients receiving once daily busulfan in their pre-transplant conditioning regimen will have the first busulfan dose scaled to their BSA instead of their body weight.
On day 1, patients with BSA ≥0.5 m2 will receive 100 mg/m2 Busulfan.
Subsequent doses of busulfan on days 2-4 will be guided by standard care, including therapeutic drug monitoring (TDM) to achieve an AUC within the therapeutic range.
|
Busulfan is a cell cycle non-specific alkylating agent which is approved by the Food and Drug Administration (FDA) and is commercially available.
|
|
Eksperimentel: Group B
Patients receiving once daily busulfan in their pre-transplant conditioning regimen will have the first busulfan dose scaled to their BSA instead of their body weight.
On day 1, patients with BSA <0.5 m2 the dose will be selected from a BSA-banded dosing table.
Subsequent doses of busulfan on days 2-4 will be guided by standard care, including therapeutic drug monitoring (TDM) to achieve an AUC within the therapeutic range.
|
Busulfan is a cell cycle non-specific alkylating agent which is approved by the Food and Drug Administration (FDA) and is commercially available.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants who achieve a therapeutic drug exposure after the first dose of Busulfan
Tidsramme: 1 day
|
Dosing for patients in Group A (BSA >=0.5m2) will be scaled to Body Surface Area, and patients in Group B (BSA <0.5m2) will be dosed based on the infant dosing table for Day 1 dose.
The value range for therapeutic drug exposure is 36,000 μM/min (Lower Bound) - 6,000 μM/min (Upper Bound)
|
1 day
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Glutathione sample concentration over the 4-day course of busulfan administration.
Tidsramme: 4 days
|
Plasma glutathione samples will be obtained daily to determine glutathione concentration over the 4 days busulfan is administered.
A 4-day total of gluathione sample concentration will be reported.
|
4 days
|
|
Number of participants with sinusoidal obstruction
Tidsramme: 100 days post transplant
|
Target adverse events (SOS, engraftment failure) will be tracked in all patients for the first 100 days post-transplant.
|
100 days post transplant
|
|
Number of participants with engraftment failure
Tidsramme: 100 days post transplant
|
Target adverse events (SOS, engraftment failure) will be tracked in all patients for the first 100 days post-transplant.
|
100 days post transplant
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. september 2026
Primær færdiggørelse (Anslået)
1. september 2030
Studieafslutning (Anslået)
1. september 2031
Datoer for studieregistrering
Først indsendt
25. august 2026
Først indsendt, der opfyldte QC-kriterier
25. august 2026
Først opslået (Faktiske)
28. august 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
28. august 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
25. august 2026
Sidst verificeret
1. august 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 26-024352
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
UBESLUTET
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ja
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ja
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .